Jaguar Animal Health (JAGX) Price & Analysis

Compare

2,343 Followers

JAGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.93 - $35.25

Previous CloseN/A

Volume188.05K

Average Volume (3M)98.59K

Market Cap

$3.96M

Enterprise Value$32.26M

Total Cash (Recent Filing)$5.69M

Total Debt (Recent Filing)$38.34M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Nov 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.26

Shares Outstanding1,914,430

10 Day Avg. Volume104,105

30 Day Avg. Volume98,592

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap8.14

Enterprise Value/Revenue2.80

Enterprise Value/Gross Profit3.41

Enterprise Value/Ebitda-0.84

Forecast

1Y Price Target

$2.50

Price Target Upside19.05% Upside

Rating ConsensusHold

Number of Analyst Covering1

Jaguar Animal Health News

Jaguar Health reports Q2 EPS ($10.25) vs. ($2.66) last year

Reports Q2 revenue $3M vs. $2.7M last year. Published first on TheFly – the ultimate source for real-time,...

3d ago

JAGX

Jaguar Health Reports Increased Losses Amid Rising Expenses

Jaguar Animal Health Inc. ( ($JAGX) ) has released its Q2 earnings. Here is a breakdown of the...

2d ago

JAGX

Jaguar Health Extends Market Offering Agreement

Jaguar Animal Health ( ($JAGX) ) just unveiled an update. On August 14, 2025, Jaguar Health, Inc. announced...

3d ago

JAGX

Jaguar Health initiates enrollment in study of Canalevia-CA1 drug for dogs

Jaguar Health (JAGX) announced that four dogs have now been enrolled in Jaguar’s ongoing field study of Canalevia-CA1,...

1M ago

JAGX

Jaguar Health announces coca access, benefit sharing agreement authorization

Jaguar Health (JAGX) announced that an access and benefit sharing agreement focused on two cultivated species of the...

1M ago

JAGX

Jaguar Animal Health Issues Series M Preferred Stock

Jaguar Animal Health ( ($JAGX) ) has provided an announcement. On June 27, 2025, Jaguar Health, Inc. entered...

2M ago

JAGX

Jaguar Health announces initial proof-of-concept results on crofelemer

Jaguar Health (JAGX) family companies Napo Pharmaceuticals and Napo Therapeutics announced that initial proof-of-concept results show that a...

2M ago

JAGX

Jaguar Health board authorizes crypto as treasury reserve asset

Jaguar Health (JAGX) Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve...

2M ago

JAGX

Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs

Jaguar Health (JAGX) announced that the company plans to pursue approval from the European Medicines Agency’s Committee for...

2M ago

JAGX

Jaguar Animal Health Extends Maturity Date for Notes

Jaguar Animal Health ( ($JAGX) ) has provided an announcement. On June 24, 2025, Jaguar Health, Inc. announced...

2M ago

JAGX

Jaguar Health provides update on orphan disease intestinal failure program

Jaguar Health (JAGX) provided updates on the company’s orphan disease intestinal failure program. Jaguar, through Jaguar family companies...

2M ago

JAGX

Jaguar Health files to sell 507.4K shares of common stock for holders

16:35 EDT Jaguar Health (JAGX) files to sell 507.4K shares of common stock for holders Published first on...

2M ago

JAGX

Jaguar Health establishes first study site for Canalevia-CA1 field study

Jaguar Health (JAGX) announced that the first study site has been established for Jaguar’s field study of Canalevia-CA1,...

2M ago

JAGX

Jaguar Health provides update on Type C meeting with FDA

Jaguar Health (JAGX) provided a recap on the company’s assessment of the in-person Type C Meeting on May...

2M ago

JAGX

JAGX FAQ

What was Jaguar Animal Health’s price range in the past 12 months?

Jaguar Animal Health lowest stock price was $1.93 and its highest was $35.25 in the past 12 months.

What is Jaguar Animal Health’s market cap?

Jaguar Animal Health’s market cap is $3.96M.

When is Jaguar Animal Health’s upcoming earnings report date?

Jaguar Animal Health’s upcoming earnings report date is Nov 12, 2025 which is in 87 days.

How were Jaguar Animal Health’s earnings last quarter?

Jaguar Animal Health released its earnings results on Aug 14, 2025. The company reported -$10.26 earnings per share for the quarter, missing the consensus estimate of -$7.13 by -$3.13.

Is Jaguar Animal Health overvalued?

According to Wall Street analysts Jaguar Animal Health’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jaguar Animal Health pay dividends?

Jaguar Animal Health does not currently pay dividends.

What is Jaguar Animal Health’s EPS estimate?

Jaguar Animal Health’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jaguar Animal Health have?

Jaguar Animal Health has 1,914,430 shares outstanding.

What happened to Jaguar Animal Health’s price movement after its last earnings report?

Jaguar Animal Health reported an EPS of -$10.26 in its last earnings report, missing expectations of -$7.13. Following the earnings report the stock price went down -20.077%.

Which hedge fund is a major shareholder of Jaguar Animal Health?

Currently, no hedge funds are holding shares in JAGX

Company Description

Jaguar Animal Health

Jaguar Animal Health, Inc. (JAGX) is a biotechnology company focused on developing and commercializing innovative animal health products for the veterinary market. The company specializes in the development of therapeutics for companion animals and livestock, particularly targeting gastrointestinal health and other unmet medical needs. Jaguar's core products include a range of prescription medications and nutraceuticals aimed at enhancing the health and well-being of animals, leveraging its proprietary technology platforms to create effective solutions.

Jaguar Animal Health (JAGX) Earnings & Revenues

Historic Earnings Reports

JAGX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive breakthroughs in medical research with crofelemer and ongoing financial challenges. While there were significant advancements in clinical trials and potential regulatory approvals, the financial metrics showed a decline in revenue and increased losses.View all JAGX earnings summaries

JAGX Stock 12 Month Forecast

Average Price Target

$2.50

▲(19.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","654751":"$654,751","163687.75":"$163,687.8","327375.5":"$327,375.5","491063.25":"$491,063.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,163687.75,327375.5,491063.25,654751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2021","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.02,2.06,2.1,2.14,2.18,2.2199999999999998,2.26,2.3,2.34,2.38,2.42,2.46,{"y":2.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.02,2.06,2.1,2.14,2.18,2.2199999999999998,2.26,2.3,2.34,2.38,2.42,2.46,{"y":2.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.02,2.06,2.1,2.14,2.18,2.2199999999999998,2.26,2.3,2.34,2.38,2.42,2.46,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":654750.44,"date":1588291200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":654750.44,"date":1612137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":546749.44,"date":1625097600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408374.6,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239625.22,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.5,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.87,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.06,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >